Investors
Header One
Header Two
Header Three
Header Four
Header Five
Header Six
Header Blue
Header Green
Paragraph. SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
Buttonblockquote
Table
Employee | Salary | |
---|---|---|
John Doe | $1 | Because that’s all Steve Jobs needed for a salary. |
Jane Doe | $100K | For all the blogging she does. |
Fred Bloggs | $100M | Pictures are worth a thousand words, right? So Jane x 1,000. |
Jane Bloggs | $100B | With hair like that?! Enough said… |
Unordered Lists (Nested)
- List item one
- List item one
- List item one
- List item two
- List item three
- List item four
- List item two
- List item three
- List item four
- List item one
- List item two
- List item three
- List item four
Ordered List (Nested)
- List item one -start at 8
- List item one
- List item one -reversed attribute
- List item two
- List item three
- List item four
- List item two
- List item three
- List item four
- List item one
- List item two
- List item three
- List item four